phawareness.blogspot.com
"BLOGGING FOR PULMONARY HYPERTENSION AWARENESS": Shaye's Story (written by her mother, Teresa)
http://phawareness.blogspot.com/2010/11/shayes-story-written-by-her-mother.html
BLOGGING FOR PULMONARY HYPERTENSION AWARENESS". Monday, November 22, 2010. Shaye's Story (written by her mother, Teresa). Here is our story of PH and how it all began. Was our reaction. They said she needed to be taken to the Texas Childrens hospitals ER. I left work and went by to get the xrays to take with me. Picked up Shaye, while my husband stayed home with the other 3 children. We left for the hospital which was about a 30 minute drive from Katy where we live. Subscribe to: Post Comments (Atom).
hcp.remodulin.com
Healthcare Professional PAH Resources | Practice
http://hcp.remodulin.com/hcp/resources-for-your-practice.aspx
For PAH (WHO Group 1) to diminish symptoms associated with exercise and to diminish. The rate of clinical deterioration in patients transitioning from Flolan. Safety and Side Effects. Diagnosis and Evaluation of PAH. Optimizing the Parenteral Conversation. E-mail address is required. Invalid e-mail address format. Resources for your Practice and Patients. For offices and centers). A comprehensive reference tool to help educate physicians or hospitals about subcutaneous (SC) and intravenous (IV) Remodulin.
hcp.remodulin.com
Clinical Studies
http://hcp.remodulin.com/hcp/clinical-studies.aspx
For PAH (WHO Group 1) to diminish symptoms associated with exercise and to diminish. The rate of clinical deterioration in patients transitioning from Flolan. Safety and Side Effects. Diagnosis and Evaluation of PAH. Optimizing the Parenteral Conversation. E-mail address is required. Invalid e-mail address format. Power of a continuous prostacyclin. It may be administered as a continuous subcutaneous infusion or continuous intravenous infusion. Remodulin SC and IV are bioequivalent. Figure adapted from L...
hcp.remodulin.com
Optimizing the Parenteral Conversation
http://hcp.remodulin.com/hcp/parenteral-discussion.aspx
For PAH (WHO Group 1) to diminish symptoms associated with exercise and to diminish. The rate of clinical deterioration in patients transitioning from Flolan. Safety and Side Effects. Diagnosis and Evaluation of PAH. Optimizing the Parenteral Conversation. E-mail address is required. Invalid e-mail address format. Optimizing the Parenteral Therapy Conversation and Increasing Patient Understanding. Healthcare Provider Patient Communication. Four steps to Remodeling the Dialogue. The way that providers com...
hcp.remodulin.com
SPS Providers | Patient & Practice Support | Referral Form
http://hcp.remodulin.com/hcp/working-with-sps-providers.aspx
For PAH (WHO Group 1) to diminish symptoms associated with exercise and to diminish. The rate of clinical deterioration in patients transitioning from Flolan. Safety and Side Effects. Diagnosis and Evaluation of PAH. Optimizing the Parenteral Conversation. E-mail address is required. Invalid e-mail address format. Working with SPS Providers. Specialty Pharmacy Services (SPS) providers function as an extension of the healthcare team to provide services, including. 2 SPS providers are available. SPS servic...
hcp.remodulin.com
Intravenous Prostacyclin Pump Options | Continuous Infusion
http://hcp.remodulin.com/hcp/iv-pump-information.aspx
For PAH (WHO Group 1) to diminish symptoms associated with exercise and to diminish. The rate of clinical deterioration in patients transitioning from Flolan. Safety and Side Effects. Diagnosis and Evaluation of PAH. Optimizing the Parenteral Conversation. E-mail address is required. Invalid e-mail address format. Find the right pump for your patients. Then, work with your patients to select the pump that’s right for them. Click patient to find pump. This is an actual Remodulin patient. Here are some cre...
hcp.remodulin.com
Transitioning from Flolan
http://hcp.remodulin.com/hcp/transitioning-from-flolan.aspx
For PAH (WHO Group 1) to diminish symptoms associated with exercise and to diminish. The rate of clinical deterioration in patients transitioning from Flolan. Safety and Side Effects. Diagnosis and Evaluation of PAH. Optimizing the Parenteral Conversation. E-mail address is required. Invalid e-mail address format. For patients requiring transition from Flolan. To see full clinical trial and results. Transition protocol from Remodulin Prescribing Information. Patients are individually titrated to a dose t...
hcp.remodulin.com
Infused Prostacyclin Therapy | Frequently Asked Questions
http://hcp.remodulin.com/hcp/faqs.aspx
For PAH (WHO Group 1) to diminish symptoms associated with exercise and to diminish. The rate of clinical deterioration in patients transitioning from Flolan. Safety and Side Effects. Diagnosis and Evaluation of PAH. Optimizing the Parenteral Conversation. E-mail address is required. Invalid e-mail address format. Here are some of the most commonly asked questions about Remodulin and pulmonary arterial hypertension (PAH). What is pulmonary arterial hypertension (PAH)? For patients requiring transition fr...
hcp.remodulin.com
Prostacyclin Therapy | Diminish Exercise Symptoms | Flolan Transition Study
http://hcp.remodulin.com/hcp/flolan-transition-study.aspx
For PAH (WHO Group 1) to diminish symptoms associated with exercise and to diminish. The rate of clinical deterioration in patients transitioning from Flolan. Safety and Side Effects. Diagnosis and Evaluation of PAH. Optimizing the Parenteral Conversation. E-mail address is required. Invalid e-mail address format. In a clinical study, 93% of patients (13 of 14) successfully transitioned from Flolan to Remodulin. In patients with PAH requiring transition from Flolan. During the transition period, patients...
hcp.remodulin.com
Supporting New Patients
http://hcp.remodulin.com/hcp/supporting-new-patients.aspx
For PAH (WHO Group 1) to diminish symptoms associated with exercise and to diminish. The rate of clinical deterioration in patients transitioning from Flolan. Safety and Side Effects. Diagnosis and Evaluation of PAH. Optimizing the Parenteral Conversation. E-mail address is required. Invalid e-mail address format. Provide the support your patients need. United Therapeutics is committed to making sure patients have the resources and information. Describe the Remodulin options. Inform patients about support.